Partners launch trial of novel HIV vaccine in Africa
A Phase I clinical trial of a novel T cell-inducing HIV vaccine candidate has launched in Africa to evaluate immune responses to highly networked HIV T-cell epitopes.
The trial is a collaboration between The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI. A team of African principal investigators will lead the clinical research in South Africa and Zimbabwe.
The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on 28 July 2025.
Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa.
The trial will enrol approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART).
Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses.
ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. The programme is funded by the Gates Foundation.
HIV prevention and therapy
The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa.
To determine the vaccine candidate’s potential for relevance in sub-Saharan Africa, where disease burden is greatest, the researchers say it is essential that the candidate be tested within communities affected by the epidemic.
“This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI’s sponsorship, ReiThera’s GRAd technology, the Ragon Institute’s innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world,” said Dr Tariro Makadzange, Clinical Trial Lead, Mutala Trust.
The vaccine candidate is designed to engage the immune system to recognise and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector.
This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions.
The trial will also assess the safety and immune response in people living with HIV and the data will be used to assess the suitability of the vaccine as a HIV therapeutic and curative intervention.
Diana Turner, Senior Digital Content Editor, DDW
